In preclinical studies, GPC3-specific ADCs showed significant efficacy in GPC3-positive Hep3B and A431-GPC3 cells, exhibiting robust tumoricidal action and highlighting the therapeutic promise of ADCs for HCC [305]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.